US OptionsDetailed Quotes
HIMS241129C39000
- 0.05
- 0.000.00%
15min DelayTrading Nov 20 12:16 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume21 Open Interest39.00Strike Price0.00Turnover140.77%IV37.28%PremiumNov 29, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0310Delta0.0160Gamma568.90Leverage Ratio-0.0304Theta0.0001Rho17.65Eff Leverage0.0022Vega
Hims & Hers Health Stock Discussion
Looking forward to close abv 30 this week
This is the best stock to own now for long term growth
up nearly 4% in overnight trading following Trump’s nomination of Marty Makary as Head of the FDA.
Dr. Makary currently serves as the Chief Medical Officer of Sesame, a telehealth platform that also offers compounded versions of GLP-1s.
Pre market is 26.35 +3.6%. Strong start to potentially revisit 30 this week.
Overview
Hims & Hers Health (HIMS) has been a standout performer in 2024, delivering an impressive 194.94% year-to-date return. The company has demonstrated significant growth momentum, driven by strong fundamentals and increasing investor confidence. The recent technical breakout highlights continued upside potential for the stock.
Current Price Analysis
• Current Price (Nov 22, 2024): $25.33
• Daily Change: +$1.18 (+4.89%)
• Post-Mar...
$CrowdStrike (CRWD.US)$ | Stifel analyst Adam Borg maintains CrowdStrike Holdings with a Buy and raises the price target from $300 to $375.
$Alibaba (BABA.US)$ | Barclays analyst Jiong Shao maintains Alibaba with a buy rating, and adjusts the target price from $137 to $130.
$Robinhood (HOOD.US)$ | Bernstein analyst Gautam Chhugani maintain...
No comment yet